Reduction of mortality, cardiac damage, and cerebral damage by IL-1 inhibition in a murine model of TTP

2.

Sukumar

S

,

Lämmle

B

,

Cataland

SR

.

Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management

.

J Clin Med

.

2021

;

10

(

3

):

536

.

3.

Dutt

T

,

Shaw

RJ

,

Stubbs

M

, et al.

Real-world experience with caplacizumab in the management of acute TTP

.

Blood

.

2021

;

137

(

13

):

1731

-

1740

.

4.

Nichols

L

,

Berg

A

,

Rollins-Raval

MA

,

Raval

JS

.

Cardiac injury is a common postmortem finding in thrombotic thrombocytopenic purpura patients: is empiric cardiac monitoring and protection needed?

.

Ther Apher Dial

.

2015

;

19

(

1

):

87

-

92

.

5.

Chaturvedi

S

,

Abbas

H

,

McCrae

K

.

Increased morbidity during long term follow up of survivors of thrombotic thrombocytopenic purpura

.

Am J Hematol

.

2015

;

90

(

10

):

E208

.

6.

Balasubramaniyam

N

,

Yandrapalli

S

,

Kolte

D

,

Pemmasani

G

,

Janakiram

M

,

Frishman

WH

.

Cardiovascular complications and their association with mortality in patients with thrombotic thrombocytopenic purpura

.

Am J Med

.

2021

;

134

(

2

):

e89

-

e97

.

7.

Courties

G

,

Moskowitz

MA

,

Nahrendorf

M

.

The innate immune system after ischemic injury — lessons to be learned from the heart and brain

.

JAMA Neurol

.

2014

;

71

(

2

):

233

-

236

.

8.

Dinarello

CA

.

Overview of the IL-1 family in innate inflammation and acquired immunity

.

Immunol Rev

.

2018

;

281

(

1

):

8

-

27

.

9.

Murray

KN

,

Parry-Jones

AR

,

Allan

SM

.

Interleukin-1 and acute brain injury

.

Front Cell Neurosci

.

2015

;

9

:

18

.

10.

Toldo

S

,

Mezzaroma

E

,

Bressi

E

, et al.

Interleukin-1β blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse

.

J Cardiovasc Pharmacol

.

2014

;

64

(

1

):

1

-

6

.

11.

Toldo

S

,

Seropian

IM

,

Mezzaroma

E

, et al.

Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury

.

J Mol Cell Cardiol

.

2011

;

51

(

2

):

244

-

251

.

12.

Abbate

A

,

Van Tassell

BW

,

Seropian

IM

, et al.

Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse

.

Eur J Heart Fail

.

2010

;

12

(

4

):

319

-

322

.

13.

Boutin

H

,

LeFeuvre

RA

,

Horai

R

,

Asano

M

,

Iwakura

Y

,

Rothwell

NJ

.

Role of IL-1α and IL-1β in ischemic brain damage

.

J Neurosci

.

2001

;

21

(

15

):

5528

-

5534

.

14.

Lugrin

J

,

Parapanov

R

,

Milano

G

, et al.

The systemic deletion of interleukin-1α reduces myocardial inflammation and attenuates ventricular remodeling in murine myocardial infarction

.

Sci Rep

.

2023

;

13

(

1

):

4006

.

15.

Abbate

A

,

Salloum

FN

,

Van Tassell

BW

, et al.

Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse

.

PLoS One

.

2011

;

6

(

11

):

e27923

.

16.

Abbate

A

,

Salloum

FN

,

Vecile

E

, et al.

Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction

.

Circulation

.

2008

;

117

(

20

):

2670

-

2683

.

17.

Toldo

S

,

Schatz

AM

,

Mezzaroma

E

, et al.

Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse

.

Cardiovasc Drugs Ther

.

2012

;

26

(

3

):

273

-

276

.

18.

Gorelik

M

,

Lee

Y

,

Abe

M

, et al.

IL-1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis

.

Clin Exp Immunol

.

2019

;

198

(

1

):

101

-

110

.

19.

Morton

AC

,

Rothman

AMK

,

Greenwood

JP

, et al.

The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study

.

Eur Heart J

.

2015

;

36

(

6

):

377

-

384

.

20.

Abbate

A

,

Kontos

MC

,

Grizzard

JD

, et al.

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study)

.

Am J Cardiol

.

2010

;

105

(

10

):

1371

-

1377.e1

.

21.

Abbate

A

,

Van Tassell

BW

,

Biondi-Zoccai

G

, et al.

Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]

.

Am J Cardiol

.

2013

;

111

(

10

):

1394

-

1400

.

22.

Abbate

A

,

Trankle

CR

,

Buckley

LF

, et al.

Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction

.

J Am Heart Assoc

.

2020

;

9

(

5

):

e014941

.

23.

Wada

H

,

Kaneko

T

,

Ohiwa

M

, et al.

Plasma cytokine levels in thrombotic thrombocytopenic purpura

.

Am J Hematol

.

1992

;

40

(

3

):

167

-

170

.

24.

Abbate

A

,

Wohlford

GF

,

Del Buono

MG

, et al.

Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials

.

Eur Heart J Cardiovasc Pharmacother

.

2022

;

8

(

5

):

503

-

510

.

25.

Del Buono

MG

,

Damonte

JI

,

Trankle

CR

, et al.

Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction

.

Sci Rep

.

2022

;

12

(

1

):

1254

.

26.

Motto

DG

,

Chauhan

AK

,

Zhu

G

, et al.

Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice

.

J Clin Invest

.

2005

;

115

(

10

):

2752

-

2761

.

27.

Lenting

PJ

,

Westein

E

,

Terraube

V

, et al.

An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation

.

J Biol Chem

.

2004

;

279

(

13

):

12102

-

12109

.

28.

Raines

G

,

Aumann

H

,

Sykes

S

,

Street

A

.

Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gel

.

Thromb Res

.

1990

;

60

(

3

):

201

-

212

.

29.

Tellier

E

,

Widemann

A

,

Cauchois

R

, et al.

Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severity

.

Haematologica

.

2023

;

108

(

4

):

1127

-

1140

.

30.

Benhamou

Y

,

Boelle

PY

,

Baudin

B

, et al.

Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center

.

J Thromb Haemost

.

2015

;

13

(

2

):

293

-

302

.

31.

Huang

SHS

,

Pavenski

K

,

Lee

TY

, et al.

Blood-brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study

.

Blood Adv

.

2021

;

5

(

20

):

4211

-

4218

.

32.

Alwan

F

,

Mahdi

D

,

Tayabali

S

, et al.

Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura

.

Br J Haematol

.

2020

;

191

(

5

):

868

-

874

.

33.

Falter

T

,

Schmitt

V

,

Herold

S

, et al.

Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura

.

Transfusion

.

2017

;

57

(

5

):

1152

-

1162

.

34.

Abbate

A

,

Toldo

S

,

Marchetti

C

,

Kron

J

,

Van Tassell

BW

,

Dinarello

CA

.

Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease

.

Circ Res

.

2020

;

126

(

9

):

1260

-

1280

.

35.

Vilahur

G

,

Badimon

L

.

Ischemia/reperfusion activates myocardial innate immune response: the key role of the toll-like receptor

.

Front Physiol

.

2014

;

5

:

496

.

36.

Zhang

X

,

Du

Q

,

Yang

Y

, et al.

The protective effect of Luteolin on myocardial ischemia/reperfusion (I/R) injury through TLR4/NF-κB/NLRP3 inflammasome pathway

.

Biomed Pharmacother

.

2017

;

91

:

1042

-

1052

.

37.

Mersmann

J

,

Habeck

K

,

Latsch

K

, et al.

Left ventricular dilation in toll-like receptor 2 deficient mice after myocardial ischemia/reperfusion through defective scar formation

.

Basic Res Cardiol

.

2011

;

106

(

1

):

89

-

98

.

38.

Elting

JW

,

de Jager

AE

,

Teelken

AW

, et al.

Comparison of serum S-100 protein levels following stroke and traumatic brain injury

.

J Neurol Sci

.

2000

;

181

(

1-2

):

104

-

110

.

39.

Sienkiewicz-Jarosz

H

,

Gałecka-Wolska

M

,

Bidziński

A

, et al.

Predictive value of selected biochemical markers of brain damage for functional outcome in ischaemic stroke patients

.

Neurol Neurochir Pol

.

2009

;

43

(

2

):

126

-

133

.

40.

Cavalli

G

,

Colafrancesco

S

,

Emmi

G

, et al.

Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases

.

Autoimmun Rev

.

2021

;

20

(

3

):

102763

.

41.

Dinarello

CA

,

van der Meer

JWM

.

Treating inflammation by blocking interleukin-1 in humans

.

Semin Immunol

.

2013

;

25

(

6

):

469

-

484

.

42.

Loisa

P

,

Rinne

T

,

Laine

S

,

Hurme

M

,

Kaukinen

S

.

Anti-inflammatory cytokine response and the development of multiple organ failure in severe sepsis

.

Acta Anaesthesiol Scand

.

2003

;

47

(

3

):

319

-

325

.

43.

Clausen

BH

,

Wirenfeldt

M

,

Høgedal

SS

, et al.

Characterization of the TNF and IL-1 systems in human brain and blood after ischemic stroke

.

Acta Neuropathol Commun

.

2020

;

8

(

1

):

81

.

44.

Wytrykowska

A

,

Prosba-Mackiewicz

M

,

Nyka

WM

.

IL-1β, TNF-α, and IL-6 levels in gingival fluid and serum of patients with ischemic stroke

.

J Oral Sci

.

2016

;

58

(

4

):

509

-

513

.

45.

Stein

A

,

Mohr

F

,

Laux

M

, et al.

Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis

.

Thromb Haemost

.

2012

;

107

(

4

):

769

-

774

.

46.

Mirhafez

SR

,

Zarifian

A

,

Ebrahimi

M

, et al.

Relationship between serum cytokine and growth factor concentrations and coronary artery disease

.

Clin Biochem

.

2015

;

48

(

9

):

575

-

580

.

47.

Le Besnerais

M

,

Favre

J

,

Denis

CV

, et al.

Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura

.

J Thromb Haemost

.

2016

;

14

(

10

):

1917

-

1930

.

48.

Salloum

FN

,

Chau

V

,

Varma

A

, et al.

Anakinra in experimental acute myocardial infarction--does dosage or duration of treatment matter?

.

Cardiovasc Drugs Ther

.

2009

;

23

(

2

):

129

-

135

.

49.

Nayki

UA

,

Nayki

C

,

Cetin

N

, et al.

Effect of Kineret® on ovarian ischemia reperfusion injury in a rat model

.

J Obstet Gynaecol Res

.

2016

;

42

(

11

):

1525

-

1533

.

50.

Hirik

E

,

Suleyman

B

,

Mammadov

R

, et al.

Effect of anakinra, an interleukin one beta antagonist, on oxidative testicular damage induced in rats with ischemia reperfusion

.

Rev Int Androl

.

2018

;

16

(

3

):

87

-

94

.

51.

Bendele

AM

,

Chlipala

ES

,

Scherrer

J

, et al.

Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis

.

Arthritis Rheum

.

2000

;

43

(

12

):

2648

-

2659

.

52.

Kong

Q

,

Wu

W

,

Yang

F

, et al.

Increased expressions of IL-22 and Th22 cells in the coxsackievirus B3-induced mice acute viral myocarditis

.

Virol J

.

2012

;

9

(

1

):

232

. 10.

53.

Béranger

N

,

Benghezal

S

,

Savigny

S

, et al.

Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura

.

Thromb Res

.

2019

;

181

:

29

-

35

.

54.

Gavriilaki

E

,

Anagnostopoulos

A

,

Mastellos

DC

.

Complement in thrombotic microangiopathies: unraveling Ariadne’s thread into the labyrinth of complement therapeutics

.

Front Immunol

.

2019

;

10

:

337

.

55.

May

O

,

Merle

NS

,

Grunenwald

A

, et al.

Heme drives susceptibility of glomerular endothelium to complement overactivation due to inefficient upregulation of heme oxygenase-1

.

Front Immunol

.

2018

;

9

:

3008

.

56.

Matevosyan

K

,

Sarode

R

.

Thrombosis, microangiopathies, and inflammation

.

Semin Thromb Hemost

.

2015

;

41

(

6

):

556

-

562

.

57.

Kremer Hovinga

JA

,

Heeb

SR

,

Skowronska

M

,

Schaller

M

.

Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome

.

J Thromb Haemost

.

2018

;

16

(

4

):

618

-

629

.

58.

Prevel

R

,

Roubaud-Baudron

C

,

Tellier

E

, et al.

Dysfonction endothéliale au cours du Purpura Thrombotique Thrombocytopénique : un nouvel axe de prise en charge [in French]

.

Rev Med Interne

.

2021

;

42

(

3

):

202

-

209

.

59.

Cauchois

R

,

Muller

R

,

Lagarde

M

,

Dignat-George

F

,

Tellier

E

,

Kaplanski

G

.

Is endothelial activation a critical event in thrombotic thrombocytopenic purpura?

.

J Clin Med

.

2023

;

12

(

3

):

758

.